Evidence map›Paper›PMID 29312549›Full record

ArticleOncotarget2017

The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance.

Christopher D Suarez, Junmin Wu, Sunil S Badve, Joseph A Sparano, William Kaliney, Laurie E Littlepage

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Implication ofMolecular cancer therapeutics · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Christopher D SuarezDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
Junmin WuDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
Sunil S BadveIndiana University School of Medicine, Indianapolis, IN 46202, USA.
Joseph A SparanoMontefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
William KalineyHarper Cancer Research Institute, South Bend, IN 46617, USA.
Laurie E LittlepageDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
Mike and Josie Harper Cancer Research InstituteIndiana University – Purdue University Indianapolis · USMontefiore Medical Center · USUniversity of Notre Dame · US

Funding

Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
NCATS NIH HHS UL1 TR001108
6 · The paper itself

Abstract

We previously identified the transcription factor ZNF217 (human) / Zfp217 (mouse) as an oncogene and prognostic indicator of reduced survival, increased metastasis, and reduced response to therapy in breast cancer patients. Here we investigated the role of Zfp217 in chemotherapy resistance. Preclinical animal models of Zfp217 overexpression were treated with a combination therapy of the microtubule inhibitor epothilone B, doxorubicin (Adriamycin), and cyclophosphamide (EAC). Tumors overexpressing Zfp217 increased their tumor burden compared to control tumors after treatment and accumulated a mammary gland progenitor cell population (K8

Indexed as

chemoresistancemicrovessel densitypatient-derived tumor xenografttriciribineZfp217/ZNF217

Identifiers

PMID29312549
PMCPMC5752462
OpenAlexW2734761519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.